Eli Lilly and Company: Diferență între versiuni
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
Admin (discuție | contribuții) Fără descriere a modificării |
||
Linia 1: | Linia 1: | ||
Pagina dedicata companiei Eli Lilly and Company listata cu | Pagina dedicata companiei Eli Lilly and Company listata cu simbolul US.LLY | ||
==Descriere companie== | ==Descriere companie== | ||
Eli Lilly and Company (www.lilly.com) is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The Company's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The Company's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas | Eli Lilly and Company (www.lilly.com) is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The Company's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The Company's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
< | <div class="link2buy"> | ||
[https://app.tradeville.ro/s?US.LLY Tranzactioneaza] | |||
</div> | |||
<iframe key="tradeville" path="graficSimbol/US.LLY" /> | <iframe key="tradeville" path="graficSimbol/US.LLY" /> | ||
==Ultimele stiri despre Eli Lilly and Company (US.LLY)== | ==Ultimele stiri despre Eli Lilly and Company (US.LLY)== | ||
<dynamicpagelist> | <dynamicpagelist> | ||
Linia 23: | Linia 18: | ||
</dynamicpagelist> | </dynamicpagelist> | ||
[[Categorie:US.LLY]][[Categorie:Stiri despre companii]] |
Versiunea de la data 31 octombrie 2024 16:31
Pagina dedicata companiei Eli Lilly and Company listata cu simbolul US.LLY
Descriere companie
Eli Lilly and Company (www.lilly.com) is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The Company's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The Company's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.
Grafic actiuni companie
Ultimele stiri despre Eli Lilly and Company (US.LLY)
- Investitorii in fondurile mutuale, numar record - 31 octombrie 2024
- Rata somajului in Romania ramane constanta - 03 octombrie 2024
- Fondurile mutuale ar putea ajunge la 1 mil. investitori - 13 septembrie 2024
- La Prima Ora - 28 august 2024
- Record la Fidelis - 21 august 2024
- Scaderi pe linie la BVB - 06 august 2024
- PIB-ul Romaniei, in crestere - 09 iulie 2024
- Fondurile de obligatiuni, preferate de investitori - 14 martie 2024
- Tentativa de frauda - 07 februarie 2024
- 2023, al treilea cel mai bun an la BVB - 08 ianuarie 2024